Kangzhe Pharmaceutical (00867.HK): The new improved drug ZUNVEYL, intended for treating mild to moderate Alzheimer's symptoms in adults, has had its application for market approval in China accepted.

Wisdom Financial News APP reported that Kangzhe Pharmaceutical (00867.HK) announced that the new improved drug ZUNVEYL (proposed generic name: benagranilamine cholate enteric-coated tablets) (ZUNVEYL) has obtained the new drug market approval application (NDA) from the China National Medical Products Administration (NMPA) on July 28, 2025. The product is intended for the treatment of mild to moderate symptoms of Alzheimer's disease in adults.